S. Winther

发表

Experience with S-1 in older Caucasian patients with metastatic colorectal cancer (mCRC): Findings from an observational chart review

H. Sorbye, P. Pfeiffer, C. Qvortrup, 2016, Acta oncologica.

TAS-102 plus bevacizumab in metastatic colorectal cancer - Authors' reply.

S. Möller, P. Pfeiffer, C. Qvortrup, 2020, The Lancet. Oncology.

TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial.

S. Möller, P. Pfeiffer, M. Yilmaz, 2020, The Lancet. Oncology.

Tolerability of the oral fluoropyrimidine S-1 after hand-foot syndrome-related discontinuation of capecitabine in western cancer patients

C. Punt, J. Pruijt, H. Boot, 2017, Acta oncologica.

Randomized study comparing full dose monotherapy ( S-1 followed by irinotecan ) and reduced dose combination therapy ( S-1 / oxaliplatin followed by S-1 / irinotecan ) as initial therapy for older patients with metastatic colorectal cancer

H. Sorbye, B. Glimelius, P. Österlund, 2022 .

Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial.

H. Sorbye, E. Hofsli, B. Glimelius, 2019, The lancet. Gastroenterology & hepatology.

The Prognostic Value of Pre-Treatment Circulating Biomarkers of Systemic Inflammation (CRP, dNLR, YKL-40, and IL-6) in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy—The Randomized NORDIC9-Study

H. Sorbye, E. Hofsli, B. Glimelius, 2022, Journal of clinical medicine.

Prognostic value of baseline functional status measures and geriatric screening in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy - The randomized NORDIC9-study.

H. Sorbye, E. Hofsli, P. Pfeiffer, 2022, Journal of geriatric oncology.

Quality of Life in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy—The Randomized NORDIC9-Study

H. Sorbye, S. Möller, E. Hofsli, 2021, Cancers.

Can we predict toxicity and efficacy in older patients with cancer? Older patients with colorectal cancer as an example

P. Pfeiffer, C. Qvortrup, T. Jørgensen, 2016, ESMO Open.

Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9

H. Sorbye, B. Glimelius, P. Pfeiffer, 2017, BMC Cancer.

S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma

P. Pfeiffer, J. Bjerregaard, H. A. Jensen, 2018, Cancer Chemotherapy and Pharmacology.

Frailty screening for predicting rapid functional decline, rapid progressive disease, and shorter overall survival in older patients with gastrointestinal cancer receiving palliative chemotherapy - a prospective, clinical study.

S. Möller, P. Pfeiffer, L. Minet, 2020, Journal of geriatric oncology.

A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01)

S. Detlefsen, L. Ventzel, P. Pfeiffer, 2023, BMC Cancer.

Information provision to older patients receiving palliative chemotherapy: a quality study

P. Pfeiffer, J. Ryg, C. Lindhardt, 2021, BMJ supportive & palliative care.

Tolerability of the oral fluoropyrimidine S-1 after hand-foot syndrome-related discontinuation of capecitabine in western cancer patients

C. Punt, J. Pruijt, H. Boot, 2017, Acta oncologica.

Treatment Options in Late-Line Colorectal Cancer: Lessons Learned from Recent Randomized Studies

L. Tarpgaard, S. Winther, Per Pfeiffer, 2023, Cancers.